Cipla has entered into a marketing and distribution agreement with Eli Lilly and Company India to launch a second brand of Tirzepatide in India. Under the agreement, Cipla will market the molecule under the brand name Yurpeak™. This collaboration aims to broaden the availability of Tirzepatide, initially launched by Lilly as Mounjaro® in March 2025, expanding access beyond established urban areas. Cipla aims to make a significant impact on obesity care.
Cipla Expands Diabetes & Obesity Portfolio
Cipla is partnering with Eli Lilly and Company India to market and distribute a second brand of Tirzepatide in India, marking Cipla’s entry into obesity care. The agreement, announced on October 23, 2025, grants Cipla the rights to distribute and promote Tirzepatide under the brand name Yurpeak™.
Strategic Agreement Details
This strategic agreement is designed to expand the availability of Tirzepatide across India, beyond the cities where Lilly already has a significant presence. Lilly will manufacture and supply Yurpeak™ to Cipla, ensuring consistent pricing with Lilly’s existing brand, Mounjaro®.
About Tirzepatide
Tirzepatide is a prescription medication, the first dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity.
Yurpeak™ Availability
Yurpeak™ (tirzepatide) will be available in a multi-dose, single-patient-use prefilled pen (KwikPen® presentation). Each pen will contain four fixed doses, administered once weekly, allowing for personalized treatment plans.
Source: BSE
